Sangeeta K Jain

Dr. Sangeeta K Jain


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2014 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
SJSangeeta K Jain
Sangeeta K Jain
KFKarin Fox
Karin Fox
PBPatricia Van Den Berg
Patricia Van Den Berg
AHAlexandria Hill
Alexandria Hill
SNSusan Nilsen
Susan Nilsen
KSKaren Szauter
Karen Szauter

6 December 2010 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
SJSangeeta K Jain
Sangeeta K Jain
SBSanmaan Basraon
Sanmaan Basraon
MLMichael J Loeffelholz
Michael J Loeffelholz
JPJanak Patel
Janak Patel
We studied the pattern of indeterminate HIV serological tests among pregnant women with follow-up testing in the postpartum period. Medical records of pregnant women were reviewed over a 2-year period. Of 16,596 pregnant women, 127 (0.8%) had positive HIV enzyme-linked immunoassay (ELISA) result. With Western blot (WB) test, 54 (0.33%) were positive, 43 (0.26%) were negative, and 30 (0.18%) were indeterminate. One of the 30 women (3.3%) with indeterminate WB converted to positive WB during pregnancy. White and black women were more likely to have an unconfirmed positive ELISA (indeterminate or negative WB) than Hispanics (p = 0.021). The positive WB rate for black women was significantly higher (p < 0.001) than other racial/ethnic groups. The postpartum follow-up testing of 14 women with indeterminate WB varied between 4 to 20 weeks; 16 did not have any postpartum follow-up test. The common bands in indeterminate WB were P24, P18, and nonviral proteins. The pattern of indeterminate WB result and its follow-up was variable during pregnancy and postpartum period. There is a need for development of national standards of care for indeterminate WB mothers and their infants in the postpartum period. Additional studies are needed to determine the cause of indeterminate tests, reducing their occurrence in the testing process, and the optimum time for testing in the postpartum period.

1 October 2007 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SJSangeeta K Jain
Sangeeta K Jain
AEAngela Earhart
Angela Earhart
NRNicole Ruddock
Nicole Ruddock
TWTony Wen
Tony Wen
GHGary D.V. Hankins
Gary D.V. Hankins
GSGeorge R. Saade
George R. Saade

7 October 2026 in Clinical Obstetrics and Gynecology
Verified
Journal Article
Closed access
FBFaranak Behnia
Faranak Behnia
CCCorey C. Clifford
Corey C. Clifford
SJSangeeta K Jain
Sangeeta K Jain
COChasey I. Omere
Chasey I. Omere
ACAna Collins-Smith
Ana Collins-Smith
LPLuis D. Pacheco
Luis D. Pacheco
Cardiomyopathies are uncommon but potentially life-threatening causes of cardiovascular disease in pregnancy. Pregnancy-associated hemodynamic changes may reveal unrecognized cardiomyopathy or exacerbate existing myocardial dysfunction. This review summarizes the diagnosis and management of dilated cardiomyopathy, hypertrophic cardiomyopathy, left ventricular hypertrabeculation/noncompaction cardiomyopathy, Takotsubo cardiomyopathy, and other rare cardiomyopathies during pregnancy. Our discussion will include pregnancy-specific hemodynamic considerations, risk stratification, medical management, labor and delivery planning, postpartum surveillance, and counseling regarding future pregnancy. This review does not address peripartum cardiomyopathy because it is considered separately.

13 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ACAna Collins-Smith
Ana Collins-Smith
SJSangeeta K Jain
Sangeeta K Jain
SJSunil Kumar Jain
Sunil Kumar Jain
L-citrulline is a non-protein amino acid with critical roles in perinatal and neonatal physiology through the intestinal–renal arginine–citrulline axis and nitric oxide (NO) production. During pregnancy, L-citrulline supports placental angiogenesis, vascular adaptation, and fetal growth through augmentation of arginine availability and endothelial NO production. In neonates, particularly preterm infants, developmental immaturity of citrulline and arginine synthesis contributes to hypoargininemia and may increase susceptibility to necrotizing enterocolitis, bronchopulmonary dysplasia with pulmonary hypertension, sepsis, and impaired intestinal function. Although L-citrulline has emerged as a promising modulator of NO bioavailability, prior reviews have largely focused on either adult cardiovascular disease or isolated neonatal applications, with limited integration of its mechanistic and translational relevance across the perinatal and neonatal continuum. Collectively, current evidence supports L-citrulline as a promising translational target in maternal–fetal and neonatal medicine because of its central role in vascular, inflammatory, and metabolic regulation. However, adequately powered clinical trials are needed to define optimal dosing, timing, patient selection, and long-term outcomes before routine clinical implementation can be recommended. This review provides a comprehensive evaluation of L-citrulline metabolism and its therapeutic potential from pregnancy through neonatal life, with emphasis on the intestinal–renal arginine–citrulline axis, endothelial function, and NO-mediated vascular regulation. We specifically examine the role of citrulline in key pathophysiologic mechanisms underlying maternal and neonatal disease, including endothelial dysfunction, impaired NO bioavailability, inflammation, oxidative stress, and abnormal placental vascular remodeling.